Nebivolol Almus (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Almus, is a beta‑blocker presented as an oral tablet for systemic use. It selectively blocks β1‑adrenergic receptors, is absorbed after oral administration, and produces antihypertensive effects through combined β1‑blockade and nitric‑oxide‑mediated vasodilation. It is indicated for the management of hypertension and, where approved, heart failure in adult patients.

GNH USA supplies Nebivolol Almus as a licensed, GMP‑ and GDP‑compliant international pharmaceutical supplier. The company serves hospitals, pharmacies and clinics worldwide, providing regulatory‑approved batches and supporting import documentation to ensure reliable access to this antihypertensive agent.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular conditions.

Hypertension: lowers blood pressure by reducing heart rate and peripheral resistance. Heart failure: improves cardiac output and symptoms in patients with reduced ejection fraction (where approved). Cardiovascular risk reduction: provides additional protection against adverse cardiac events in high‑risk hypertensive patients.

Nebivolol may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate. - Heart block: atrioventricular conduction disturbances. - Hypotension: significant drop in blood pressure causing faintness.

When prescribing Nebivolol, several safety considerations should be observed. - Dose titration: start low and adjust based on blood pressure and heart rate. - Cardiovascular monitoring: monitor heart rate, ECG, and blood pressure regularly. - Respiratory conditions: use cautiously in patients with asthma or COPD. - Diabetes: monitor blood glucose as beta‑blockers may mask hypoglycemia symptoms. - Drug discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Nebivolol can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Combined β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased risk of AV block. - CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, diuretics): monitor for excessive blood pressure drop. - Antidiabetic agents: observe for masked hypoglycemia symptoms. - NSAIDs: may reduce antihypertensive effect.